<p>The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropa
<ul><li>Important for exchange rate to move stably, reflecting economic fundamentals</li><li>Sharp, one-sided moves are seen recently</li><li>To take appropriate st
<p>Pivot</p> <p> (invalidation): 3154.00 Our preference</p> <p>Short positions below 3154.00 with targets at 3077.00 & 3017.00 in extension.</p> &l
Leave a Comment